News | May 25, 2021
Astrazeneca Pharma India Q4FY21 net profit up at Rs 27.27 Cr
The company has reported total income of Rs.826.40 crores for FY 2020-21
The company has reported total income of Rs.826.40 crores for FY 2020-21
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
This marks Glenmark's first synthetic decapeptide injectable approval
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Subscribe To Our Newsletter & Stay Updated
